REG - Genflow Biosciences - Publication of a Key European Patent

Genflow BiosciencesAnnouncement

21/03/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240321:nRSU6661Ha&default-theme=true

RNS Number : 6661H  Genflow Biosciences PLC  21 March 2024

THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO
CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION
(EU) NO. 596/2014 AS IT FORMS PART OF UK DOMESTIC LAW PURSUANT TO THE EUROPEAN
UNION (WITHDRAWAL) ACT 2018, AS AMENDED. UPON THE PUBLICATION OF THIS
ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS
CONSIDERED TO BE IN THE PUBLIC DOMAIN.

 

21 March 2024

 

Genflow Biosciences Plc

Announces Publication of a Key European Patent in Partnership with University
of Rochester, New York, et al.

 

Genflow Biosciences Plc (LSE:GENF) (OTCQB:GENFF) ("Genflow" or "the Company"),
an emerging leader in the field of longevity research, focused on developing
therapeutic solutions for the prevention of age-related diseases, is pleased
to announce a significant milestone in its journey. Genflow's collaborative
partners, including the University of Rochester, The Trustees of Columbia
University in the City of New York, and Albert Einstein College of Medicine,
have received confirmation that their European patent application was
published today by the European Patent Office, bearing the reference number EP
4 338 267.

 

Innovation in Age-Related Disease Prevention and Treatment

 

The patent, titled "Variants of SIRT6 for Use in Preventing and/or Treating
Age-Related Diseases," enhances the understanding and potential treatment of
diseases associated with aging by focusing on the SIRT6 gene/protein, known
for its critical role in DNA repair, metabolism, and longevity.

 

SIRT6 regulates DNA damage repair, specifically double strand breaks (DSB) and
prevents or delays aging of cells. Genflow's lead drug candidate, GF-1002,
delivers a centenarian variant of the SIRT6 gene. Genflow is currently
undertaking key Investigational New Drug (IND)-enabling development activities
that will help define the pharmacological and toxicological properties of
GF-1002 and its potential benefits, initially, for non-alcoholic
steatohepatitis (NASH) patients.

 

In 2023, the Company received positive feedback from the Federal Agency for
Medicines and Health Products in Belgium and expects a follow-up meeting in Q2
2024 to finalise design of Phase/II clinical trials. NASH, the most severe
form of non-alcoholic fatty liver disease (NAFLD) characterized by excessive
fat deposits in the liver, is usually a silent disease with few, if any,
symptoms, and effective treatments.

 

Dr. Eric Leire, CEO of Genflow commented: "This approval from the European
Patent Office highlights the innovative spirit of our collaborative team and
we are incredibly proud to be part of this pioneering research alongside such
respected institutions." He continued, "This patent represents a leap forward
in our understanding and capabilities in treating age-related conditions and
marks a significant step forward in our mission to develop effective therapies
for NASH and other age-related diseases."

 

Contacts

 Genflow Biosciences  Harbor Access
 Dr Eric Leire, CEO   Jonathan Paterson, Investor Relations
 +32-477-495-881      +1 475 477 9401
                      Jonathan.Paterson@Harbor-access.com

 

 Joint Corporate Brokers
 Clear Capital Markets          Capital Plus Partners Ltd
 Bob Roberts, +44 203 869 6080  Dominic Berger, +44 203 821 6167
                                Keith Swann, +44 0203 821 6169
                                Jon Critchley, +44 0203 821 6168

 

 

About Genflow Biosciences

 

Founded in 2020, Genflow Biosciences Plc. (LSE:GENF) (OTCQB:GENFF), a
biotechnology company headquartered in the UK with R&D facilities in
Belgium, is pioneering gene therapies to decelerate the aging process, with
the goal of promoting longer and healthier lives while mitigating the
financial, emotional, and social impacts of a fast-growing aging global
population. Genflow's lead compound, GF-1002, works through the delivery of a
centenarian variant of the SIRT6 gene which has yielded promising preclinical
results. Scheduled to begin in 2025, Genflow's clinical trial aims to explore
the potential benefits of GF-1002 in treating non-alcoholic steatohepatitis
(NASH), the most prevalent chronic liver disease for which there is no
effective treatments. Please visit www.genflowbio.com
(http://www.genflowbio.com)  and follow the Company on LinkedIn and
Twitter/X.

 

DISCLAIMER

The contents of this announcement have been prepared by, and are the sole
responsibility of, the Company.

This announcement may contain forward-looking statements. The forward-looking
statements include, but are not limited to, statements regarding the Company's
or the Directors' expectations, hopes, beliefs, intentions or strategies
regarding the future. In addition, any statement that refers to projections,
forecasts or other characterisations of future events or circumstances,
including any underlying assumptions, is a forward-looking statement. The
words "anticipate", "believe", "continue", "could", "estimate", "expect",
"intend", "may", "might", "plan", "possible", "potential", "predict",
"project", "seek", "should", "would" and similar expressions, or in each case
their negatives, may identify forward-looking statements, but the absence of
these words does not mean that a statement is not forward-looking.

Forward-looking statements include all matters that are not historical facts.
Forward-looking statements are based on the current expectations and
assumptions regarding the Company, the business, the economy and other future
conditions. Because forward-looking statements relate to the future, by their
nature, they are subject to inherent uncertainties, risks and changes in
circumstances that are difficult to predict. Forward-looking statements are
not guarantees of future performance and the Company's actual financial
condition, actual results of operations and financial performance, and the
development of the industries in which it operates or will operate, may differ
materially from those made in or suggested by the forward-looking statements
contained in this announcement. In addition, even if the Company's financial
condition, results of operations and the development of the industries in
which it operates or will operate, are consistent with the forward-looking
statements contained in this announcement, those results or developments may
not be indicative of financial condition, results of operations or
developments in subsequent periods. Important factors that could cause actual
results to differ materially from those in the forward-looking statements
include regional, national or global, political, economic, social, business,
technological, competitive, market and regulatory conditions.

Any forward-looking statement contained in this announcement applies only as
of the date of this announcement and is expressly qualified in its entirety by
these cautionary statements. Factors or events that could cause the Company's
actual plans or results to differ may emerge from time to time, and it is not
possible for the Company to predict all of them. The Company expressly
disclaims any obligation or undertaking to release publicly any updates or
revisions to any forward-looking statements contained in this announcement to
reflect any change in its expectations or any change in events, conditions or
circumstances on which any forward-looking statement contained in this
announcement is based, unless required to do so by applicable law, the
Prospectus Regulation Rules, the Listing Rules, the Disclosure Guidance and
Transparency Rules of the FCA or the UK Market Abuse Regulation

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  UPDBLGDXLDDDGSG